Should I buy or sell Cerevel Therapeutics stock right now?

10 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Cerevel Therapeutics in the last twelve months. There are currently 8 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" CERE shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in CERE, but not buy additional shares or sell existing shares. View CERE analyst ratings or view top-rated stocks .

What is Cerevel Therapeutics' stock price target for 2024?

10 Wall Street research analysts have issued 1-year price targets for Cerevel Therapeutics' shares. Their CERE share price targets range from $30.00 to $45.00. On average, they anticipate the company's stock price to reach $41.40 in the next year. This suggests that the stock has a possible downside of 1.8%. View analysts price targets for CERE or view top-rated stocks among Wall Street analysts .

How have CERE shares performed in 2024?

Cerevel Therapeutics' stock was trading at $42.40 at the beginning of 2024. Since then, CERE stock has decreased by 0.6% and is now trading at $42.14. View the best growth stocks for 2024 here .

Are investors shorting Cerevel Therapeutics?

Cerevel Therapeutics saw a increase in short interest in the month of March. As of March 31st, there was short interest totaling 9,620,000 shares, an increase of 38.2% from the March 15th total of 6,960,000 shares. Based on an average daily trading volume, of 1,510,000 shares, the days-to-cover ratio is currently 6.4 days. Currently, 11.1% of the company's shares are sold short. View Cerevel Therapeutics' Short Interest .

When is Cerevel Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 1st 2024. View our CERE earnings forecast .

How were Cerevel Therapeutics' earnings last quarter?

Cerevel Therapeutics Holdings, Inc. (NASDAQ:CERE) released its quarterly earnings results on Wednesday, November, 1st. The biotechnology company reported ($0.61) EPS for the quarter, beating the consensus estimate of ($0.63) by $0.02. During the same period last year, the business posted ($0.66) EPS.

What ETFs hold Cerevel Therapeutics' stock?

ETFs with the largest weight of Cerevel Therapeutics (NASDAQ:CERE) stock in their portfolio include ALPS Medical Breakthroughs ETF (SBIO) , First Trust Merger Arbitrage ETF (MARB) , IQ Merger Arbitrage ETF (MNA) , iShares Neuroscience and Healthcare ETF (IBRN) , AltShares Event-Driven ET (EVNT) , AltShares Merger Arbitrage ETF (ARB) , ProShares Merger ETF (MRGR) and SPDR S&P Biotech ETF (XBI) .

What other stocks do shareholders of Cerevel Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Cerevel Therapeutics investors own include Precigen (PGEN) , Arena Pharmaceuticals (ARNA) , CTI BioPharma (CTIC) , Achillion Pharmaceuticals (ACHN) , Alpha Natural Resources (ANRZQ) , Cenveo (CVO) , Hess (HES) , Palatin Technologies (PTN) , Aeterna Zentaris (AEZS) and Avid Bioservices (CDMO) .

How do I buy shares of Cerevel Therapeutics?

Shares of CERE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:CERE

Cerevel Therapeutics (CERE) Stock Price, News & Analysis

→ The Next Nvidia? (From InvestorPlace) (Ad)

Free CERE Stock Alerts

$42.14

+0.54 (+1.30%)

(As of 04/18/2024 ET)

Compare

Today's Range: $41.70
▼
$42.21
50-Day Range: $40.88
▼
$43.27
52-Week Range: $19.59
▼
$43.59

Volume: 1.28 million shs
Average Volume: 1.52 million shs
Market Capitalization: $7.65 billion

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $41.40

Get Cerevel Therapeutics alerts:

Cerevel Therapeutics MarketRank™ Stock Analysis

Analyst Rating: Hold
2.20 Rating Score
Upside/Downside: 1.8% Downside
$41.40 Price Target
Short Interest: Bearish
11.06% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 1.06
Based on 9 Articles This Week
Insider Trading: Selling Shares
$4.30 M Sold Last Quarter
Proj. Earnings Growth: Decreasing
From ($2.53) to ($2.72) Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

0.24 out of 5 stars

Medical Sector

895th out of 918 stocks

Pharmaceutical Preparations Industry

394th out of 405 stocks

1.1

Analyst's Opinion

Consensus Rating
Cerevel Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.20, and is based on 2 buy ratings, 8 hold ratings, and no sell ratings.
Amount of Analyst Coverage
Cerevel Therapeutics has only been the subject of 1 research reports in the past 90 days.

1.0

Short Interest

Percentage of Shares Shorted
11.06% of the float of Cerevel Therapeutics has been sold short.
Short Interest Ratio / Days to Cover
Cerevel Therapeutics has a short interest ratio ("days to cover") of 6.4.
Change versus previous month
Short interest in Cerevel Therapeutics has recently increased by 38.22%, indicating that investor sentiment is decreasing significantly.

0.0

Dividend Strength

Dividend Yield
Cerevel Therapeutics does not currently pay a dividend.
Dividend Growth
Cerevel Therapeutics does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for CERE.

3.4

News and Social Media Coverage

News Sentiment
Cerevel Therapeutics has a news sentiment score of 1.06. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.49 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 9 news articles for Cerevel Therapeutics this week, compared to 4 articles on an average week.
Search Interest
1 people have searched for CERE on MarketBeat in the last 30 days.
MarketBeat Follows
Only 1 people have added Cerevel Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -80% compared to the previous 30 days.

2.5

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Cerevel Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $4,302,367.00 in company stock.
Percentage Held by Insiders
Only 5.10% of the stock of Cerevel Therapeutics is held by insiders.
Percentage Held by Institutions
87.73% of the stock of Cerevel Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.0

Earnings and Valuation

Earnings Growth
Earnings for Cerevel Therapeutics are expected to decrease in the coming year, from ($2.53) to ($2.72) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Cerevel Therapeutics is -16.86, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Cerevel Therapeutics is -16.86, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Cerevel Therapeutics has a P/B Ratio of 11.36. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad InvestorPlace

The Next Nvidia?

The Next Nvidia? Wall Street legend has just uncovered one tiny Maryland company that could become the next Nvidia. Few in the media are talking about this story yet… but in the next 6 months that’s all they’ll talk about.

Go here now for this breaking story.

About Cerevel Therapeutics Stock (NASDAQ:CERE)

Cerevel Therapeutics Holdings, Inc., a clinical-stage biopharmaceutical company, develops various therapies for neuroscience diseases in the United States. It is developing Emraclidine, a positive allosteric modulator (PAM) that is in phase 1b clinical trials for the treatment of schizophrenia; and Darigabat, a PAM, which is in Phase 2 proof-of-concept trial in patients with drug-resistant focal onset seizures or focal epilepsy, as well as in phase 1 trial to treat panic symptoms model. The company's products also comprise Tavapadon, a selective dopamine D1/D5 partial agonist that is in phase 3 clinical trial for the treatment of early- and late-stage Parkinson's disease; CVL-871, a selective dopamine D1/D5 partial agonist, which is in Phase 2a clinical trial to treat dementia-related apathy; and CVL-354, a selective kappa-opioid receptor antagonist to treat major depressive disorder and substance use disorder. It is also involved in the development of an M4 agonist program for the treatment of psychosis and related indications; and PDE4 inhibitor for the treatment of psychiatric, neuroinflammatory, and other disorders. Cerevel Therapeutics Holdings, Inc. was founded in 2018 and is headquartered in Cambridge, Massachusetts.

CERE Stock Price History

30 days | 90 days | 365 days | Advanced Chart

CERE Stock News Headlines

April 18, 2024 | benzinga.com

Soon To Be Acquired Cerevel Therapeutics Reveals High Level Data From Late-Stage Parkinson's Disease Study

April 18, 2024 | msn.com

AbbVie buyout Cerevel posts late-stage win for Parkinson’s disease drug

April 18, 2024 | InvestorPlace (Ad)

The Next Nvidia?

April 18, 2024 | reuters.com

Cerevel Therapeutics' Parkinson's disease drug meets main goal in late-stage study

April 18, 2024 | finance.yahoo.com

Cerevel Therapeutics Announces Positive Topline Results for Tavapadon in Phase 3 Adjunctive Trial for People Living with Parkinson’s Disease

April 18, 2024 | globenewswire.com

Cerevel Therapeutics Announces Positive Topline Results for Tavapadon in Phase 3 Adjunctive Trial for People Living with Parkinson's Disease

April 16, 2024 | markets.businessinsider.com

Analysts Offer Insights on Healthcare Companies: Bioxcel Therapeutics (BTAI) and Unity Biotechnology (UBX)

April 12, 2024 | seekingalpha.com

AbbVie: Despite The Run, Shares Still Look Attractive, Yielding 3.67%

April 18, 2024 | InvestorPlace (Ad)

The Next Nvidia?

April 12, 2024 | americanbankingnews.com

Cerevel Therapeutics Sees Unusually High Options Volume (NASDAQ:CERE)

April 9, 2024 | americanbankingnews.com

Cerevel Therapeutics Holdings, Inc. (NASDAQ:CERE) Receives Average Rating of "Hold" from Analysts

April 5, 2024 | investing.com

Cerevel Therapeutics director sells $2.12m in stock, buys $175k worth

April 3, 2024 | uk.finance.yahoo.com

Director N Coles Sells 50,000 Shares of Cerevel Therapeutics Holdings Inc (CERE)

March 29, 2024 | wsj.com

Cerevel Therapeutics Holdings Inc.

March 29, 2024 | markets.businessinsider.com

Analysts Offer Insights on Healthcare Companies: Crispr Therapeutics AG (CRSP) and Apellis Pharmaceuticals (APLS)

March 16, 2024 | finance.yahoo.com

CERE Apr 2024 40.000 call

March 7, 2024 | markets.businessinsider.com

Cerevel Therapeutics: Hold Rating Amidst Pending AbbVie Acquisition

March 6, 2024 | markets.businessinsider.com

Analysts Offer Insights on Healthcare Companies: Praxis Precision Medicines (PRAX) and Perspective Therapeutics (CATX)

March 6, 2024 | seekingalpha.com

Cerevel Therapeutics: Parkinson's Could Be The Issue

February 28, 2024 | markets.businessinsider.com

Maintaining Hold Rating Amid ABBV-CERE Deal Progress and Rising Operational Costs

February 24, 2024 | uk.finance.yahoo.com

ABBV Mar 2024 182.500 call

February 23, 2024 | bloomberg.com

US Politicians Raise Concerns Over Capital One-Discover Deal

February 23, 2024 | uk.finance.yahoo.com

3M Healthcare Unit Solventum Joins $53 Billion US Corporate Bond Sales Spree

February 22, 2024 | markets.businessinsider.com

Analysts Offer Insights on Healthcare Companies: Intellia Therapeutics (NTLA) and Intra-Cellular Therapies (ITCI)

February 22, 2024 | finance.yahoo.com

AbbVie Selling $15 Billion Bonds to Buy ImmunoGen, Cerevel

February 21, 2024 | reuters.com

AbbVie eyes selling at least $13 bln of bonds to fund M&A, Bloomberg reports

February 21, 2024 | finance.yahoo.com

AbbVie (ABBV) Announces Appointment of New CEO Robert Michael

See More Headlines

Receive CERE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Cerevel Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 11/01/2023
Today: 4/18/2024
Next Earnings (Estimated): 5/01/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Pharmaceutical preparations
Sub-Industry: Coal & Consumable Fuels
Current Symbol: NASDAQ:CERE
CUSIP: 15677310
CIK: 767884
Web: ceres.net
Phone: 844-304-2048
Fax: N/A
Employees: 334
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $41.40
High Stock Price Target: $45.00
Low Stock Price Target: $30.00
Potential Upside/Downside: -1.8%
Consensus Rating: Hold
Rating Score (0-4): 2.20
Research Coverage: 10 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($2.50)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-432,840,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -100.14%
Return on Assets: -44.51%

Debt

Debt-to-Equity Ratio: 0.50
Current Ratio: 10.92
Quick Ratio: 10.92

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $3.71 per share
Price / Book: 11.36

Miscellaneous

Outstanding Shares: 181,580,000
Free Float: 172,316,000
Market Cap: $7.65 billion
Optionable: Optionable
Beta: 1.48

7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google

Growth stocks offer a lot of bang for your buck, and we've got the next upcoming superstars to strongly consider for your portfolio.

Get This Free Report

Key Executives

Dr. N. Anthony Coles Jr. (Age 64)
M.P.H., Executive Chairman
Comp: $1.14M
Mr. Mark Bodenrader (Age 51)
VP of Finance & Chief Accounting Officer
Comp: $496.17k
Dr. John J. Renger Ph.D. (Age 55)
Chief Scientific Officer
Comp: $779.75k
Dr. Ramiro Sanchez M.D. (Age 63)
Chief Medical Officer
Comp: $805.13k
Mr. Ronald C. Renaud Jr. (Age 55)
M.B.A., President, CEO & Director
Dr. Susan Altschuller M.B.A. (Age 42)
Ph.D., Chief Financial Officer
Mr. Matthew Calistri
Vice President of Investor Relations
Mr. Scott M. Akamine J.D. (Age 39)
Chief Legal Officer & Corporate Secretary
Comp: $444.74k
Mr. Kenneth A. DiPietro (Age 65)
Chief Human Resources Officer
Ms. Kathleen Tregoning M.A. (Age 53)
Chief Corporate Affairs Officer
Comp: $600.79k

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

CERE Stock Analysis - Frequently Asked Questions

Should I buy or sell Cerevel Therapeutics stock right now?: 10 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Cerevel Therapeutics in the last twelve months. There are currently 8 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" CERE shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in CERE, but not buy additional shares or sell existing shares.
View CERE analyst ratings or view top-rated stocks.
What is Cerevel Therapeutics' stock price target for 2024?: 10 Wall Street research analysts have issued 1-year price targets for Cerevel Therapeutics' shares. Their CERE share price targets range from $30.00 to $45.00. On average, they anticipate the company's stock price to reach $41.40 in the next year. This suggests that the stock has a possible downside of 1.8%.
View analysts price targets for CERE or view top-rated stocks among Wall Street analysts.
How have CERE shares performed in 2024?: Cerevel Therapeutics' stock was trading at $42.40 at the beginning of 2024. Since then, CERE stock has decreased by 0.6% and is now trading at $42.14.
View the best growth stocks for 2024 here.
Are investors shorting Cerevel Therapeutics?: Cerevel Therapeutics saw a increase in short interest in the month of March. As of March 31st, there was short interest totaling 9,620,000 shares, an increase of 38.2% from the March 15th total of 6,960,000 shares. Based on an average daily trading volume, of 1,510,000 shares, the days-to-cover ratio is currently 6.4 days. Currently, 11.1% of the company's shares are sold short.
View Cerevel Therapeutics' Short Interest.
When is Cerevel Therapeutics' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 1st 2024.
View our CERE earnings forecast.

How were Cerevel Therapeutics' earnings last quarter?: Cerevel Therapeutics Holdings, Inc. (NASDAQ:CERE) released its quarterly earnings results on Wednesday, November, 1st. The biotechnology company reported ($0.61) EPS for the quarter, beating the consensus estimate of ($0.63) by $0.02. During the same period last year, the business posted ($0.66) EPS.
What ETFs hold Cerevel Therapeutics' stock?: ETFs with the largest weight of Cerevel Therapeutics (NASDAQ:CERE) stock in their portfolio include ALPS Medical Breakthroughs ETF (SBIO), First Trust Merger Arbitrage ETF (MARB), IQ Merger Arbitrage ETF (MNA), iShares Neuroscience and Healthcare ETF (IBRN), AltShares Event-Driven ET (EVNT), AltShares Merger Arbitrage ETF (ARB), ProShares Merger ETF (MRGR) and SPDR S&P Biotech ETF (XBI).
What other stocks do shareholders of Cerevel Therapeutics own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Cerevel Therapeutics investors own include Precigen (PGEN), Arena Pharmaceuticals (ARNA), CTI BioPharma (CTIC), Achillion Pharmaceuticals (ACHN), Alpha Natural Resources (ANRZQ), Cenveo (CVO), Hess (HES), Palatin Technologies (PTN), Aeterna Zentaris (AEZS) and Avid Bioservices (CDMO).
How do I buy shares of Cerevel Therapeutics?: Shares of CERE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:CERE) was last updated on 4/18/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Cerevel Therapeutics (CERE) Stock Price, News & Analysis

Cerevel Therapeutics MarketRank™ Stock Analysis

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

News and Social Media Coverage

News Sentiment

News Coverage This Week

Search Interest

MarketBeat Follows

Company Ownership

Earnings and Valuation

About Cerevel Therapeutics Stock (NASDAQ:CERE)

CERE Stock Price History

CERE Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

Insiders & Institutions

CERE Stock Analysis - Frequently Asked Questions

Overall MarketRank^™